Sort   by:  
 Page size 
MetabolomicsProteasome Inhibitor Related Cardiotoxicity (part I)
Not available
ORGANISM(S): Mus musculus 
ST001846 | MetabolomicsWorkbench
MetabolomicsProteasome Inhibitor Related Cardiotoxicity (part II)
Not available
ORGANISM(S): Mus musculus 
ST001858 | MetabolomicsWorkbench
MetabolomicsFate and PPARγ and STATs-driven effects of the mitochondrial complex I inhibitor tebufenpyrad in liver cells revealed with multi-omics.
The biological effects of the pesticide and mitochondrial complex I inhibitor tebufenpyrad (TEBU) on liver cells were investigated by combining proteomics and metabolomics. Both cell culture media and cellular lysates were analyzed in dose-response and kinetic experiments on the HepaRG cell line. Re...
2024-02-07 | MTBLS4063 | MetaboLights
TranscriptomicsTranscription profiling of human MCF-7 cells treated with proteasome inhibitor MG132 and either dexamethasone or 17b-estradiol
The objective of the study was to investigate the effect of proteasome inhibition on glucocorticoid and estrogen receptor regulated gene expression. Experiment Overall Design: MCF-7 cells were treated with proteasome inhibitor (MG132), dexamethasone, 17b-estradiol or MG132 plus dexamethasone or MG13...
ORGANISM(S): Homo sapiens 
2008-06-20 | E-GEOD-8383 | biostudies-arrayexpress
ProteomicsPTEN DEFICIENCY LEADS TO PROTEASOME ADDICTION, A NOVEL VULNERABILITY IN GLIOBLASTOMA
Glioblastoma (GBM) is the most common primary brain tumor in adults with a median survival of approximately 15 months, therefore, more effective treatment options for GBM are required. To identify new drugs targeting glioblastomas, we performed a high throughput drug screen using patient-derived neu...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2020-12-04 | MSV000086560 | MassIVE
TranscriptomicsSubunit-specific vs. non-selective proteasome modulation in limiting inflammation in experimental colitis
Inflammatory bowel disease (IBD), comprising CrohnM-BM-4s disease and Ulcerative colitis, is characterized by chronic relapsing inflammation of the gut. It has been shown that increased proteasomal activity is associated with the expression of immunoproteasomes, which enhances NF-kB activation and t...
ORGANISM(S): Mus musculus 
2010-07-06 | E-GEOD-18163 | biostudies-arrayexpress
TranscriptomicsProteasome inhibition blocks estrogen-dependent gene transcription by decreasing histone H2B monoubiquitination in human breast cancer cells
The estrogen receptor-alpha (ERα) determines breast cancer cell phenotype and is a prognostic indicator. A better understanding of the mechanisms controlling ERα function may uncover improved strategies for the treatment of breast cancer. Proteasome inhibition was previously reported to regulate est...
ORGANISM(S): Homo sapiens 
2011-11-22 | E-GEOD-30931 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of human HEK293 cells treated with the proteasome inhibitor epoxomicin
The objective of this study is to identify the genes that are up-regulated amid proteasome dysfunction to facilitate the discovery of proteolytic pathways that are activated as a compensatory response to proteasome inhibition. Proteasome is a large multi-component proteolytic complex in the cell. It...
ORGANISM(S): Homo sapiens 
2009-01-27 | E-GEOD-14429 | biostudies-arrayexpress
GenomicsGenomewide T. brucei RNAi screen using proteasome inhibitor
Genomewide T. brucei RNAi screen using proteasome inhibitor
PRJEB31738 | ENA
TranscriptomicsCCRF-CEM Prednisolone and MG132 treatments at 4h
Background: The combination of Proteasome inhibitor with Glucocorticoid is one of the most promising antileukemic treatments. Both agents act through pluripotent signal mediators. The two types of agents inhibit key signals that are considered crucial to their effects on malignant cells. Methodology...
ORGANISM(S): Homo sapiens 
2011-05-11 | E-GEOD-29136 | biostudies-arrayexpress
Sort   by:  
 Page size